SUNMO
A chemotherapy-free bispecific plus ADC doublet beat salvage chemotherapy in relapsed large B-cell lymphoma.
Met its primary PFS endpoint (2025); fixed-duration, outpatient regimen. Positions mosun-pola as an alternative for patients not fit for CAR-T.
Setting
R/R LBCL, transplant-ineligible: mosunetuzumab + polatuzumab vs R-GemOx
Phase
Phase 3
Sponsor
Roche
Registry
Headline result
PFS improved (HR reported 2025).
Reported
2025
Enrolled
208
Pages like this
not linked directly; found by shared links- IdeactDNA-guided escalation and de-escalation in frontline DLBCL
- TargetCD79b
- TrialPOLARIX
- Key paperEPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T
Shares CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab), Mosunetuzumab, Diffuse large B-cell lymphoma.
- Key paperPOLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma
- CompanyRoche / Genentech
Shares Mosunetuzumab, Polatuzumab vedotin, Diffuse large B-cell lymphoma.
- TargetCD20
- TargetCD3